[PDF][PDF] Evidence of recent Epstein-Barr virus reactivation in individuals experiencing Long COVID
MJ Peluso, TM Deveau, SE Munter, D Ryder, A Buck… - medRxiv, 2022 - medrxiv.org
MJ Peluso, TM Deveau, SE Munter, D Ryder, A Buck, S Lu
medRxiv, 2022•medrxiv.orgBACKGROUND Intense efforts are underway to understand the biologic mechanisms that
drive Long COVID (LC), a type of post-acute sequelae of SARS-CoV-2 infection (PASC)
characterized by persistent or recurrent symptoms that interfere with quality of life
(Nalbandian et al., 2021; 2021). Prior work has identified immune activation (Peluso et al.,
2021a; Phetsouphanh et al., 2022), microvascular dysfunction (Pretorius et al., 2021;
Wenzel et al., 2021), autoimmunity (Seeßle et al., 2021; Su et al., 2022), and SARS-CoV-2 …
drive Long COVID (LC), a type of post-acute sequelae of SARS-CoV-2 infection (PASC)
characterized by persistent or recurrent symptoms that interfere with quality of life
(Nalbandian et al., 2021; 2021). Prior work has identified immune activation (Peluso et al.,
2021a; Phetsouphanh et al., 2022), microvascular dysfunction (Pretorius et al., 2021;
Wenzel et al., 2021), autoimmunity (Seeßle et al., 2021; Su et al., 2022), and SARS-CoV-2 …
BACKGROUND
Intense efforts are underway to understand the biologic mechanisms that drive Long COVID (LC), a type of post-acute sequelae of SARS-CoV-2 infection (PASC) characterized by persistent or recurrent symptoms that interfere with quality of life (Nalbandian et al., 2021; 2021). Prior work has identified immune activation (Peluso et al., 2021a; Phetsouphanh et al., 2022), microvascular dysfunction (Pretorius et al., 2021; Wenzel et al., 2021), autoimmunity (Seeßle et al., 2021; Su et al., 2022), and SARS-CoV-2 viral persistence (Chertow et al.,
medrxiv.org
